1. ALLA AKTIER
  2. NYHETER
  3. LIPUM

Lipum

Nyheter Lipum Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Lipum AB – interim report for the period January-June 2023

MARKN.

Lipum AB (publ) has published the interim report for period January to June for 2023. Below is a summary, a complete report (only in Swedish) is available on the company's website.

CEO Einar Pontén comments: “I am very pleased with this development. We will now accelerate the implementation of our Phase 1 clinical trial.”

Financial summary January - June 2023

  • Net sales: KSEK 0 (0)
  • Result after financial items: -21 122 KSEK (-15 167)
  • Cash and cash equivalents as of June 31: 12 364 KSEK (18 783)

Significant events during the period January - June 2023

  • Carl-Johan Spak was elected as new board member of Lipum AB.
  • Lipum had a consultative meeting with the Swedish Medical Products Agency.
  • Decision on rights issue.

Significant events after the period

  • Capital contribution from rights issue 15.3 MSEK before overheads of 8%.
  • Collaboration with researchers at Karolinska Institute initiated.
  • Publication of a scientific article on BSSL.

CEO Einar Pontén comments on the report in a live webcast on August 31 at 09:00, link.

Contacts
Einar Pontén, CEO
einar.ponten@lipum.se
+46 70 578 34 95
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum AB Delarsrapport Jan Juni 2023

Datum 2023-08-31, kl 08:00
Källa MFN
Bifogade filer
Lipum AB Delarsrapport Jan Juni 2023